![Journal cover image](https://secure.syndetics.com/index.aspx?isbn=/lc.gif&issn=1097-6744&client=dukeuniv)
The periprocedural management of novel oral anticoagulants in patients with nonvalvular atrial fibrillation: rationale and a summary of the available evidence from phase 3 clinical trials.
Publication
, Journal Article
Krishnamoorthy, A; Sherwood, MW; Lopes, RD; Becker, RC
Published in: Am Heart J
March 2015
The novel oral anticoagulants (NOACs) have rapidly emerged as an alternative therapy to warfarin. Several recent phase 3 randomized control trials have demonstrated the efficacy and safety of the NOACs in the treatment for patients with nonvalvular atrial fibrillation. As the NOACs are incorporated in clinical practice, questions have begun to arise concerning their optimal use in commonly encountered situations. In this review, we provide a summary of the available evidence from the phase 3 randomized control trials specifically with regard to 1 such scenario, the periprocedural management of NOACs, with a goal of providing guidance for practicing clinicians.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Am Heart J
DOI
EISSN
1097-6744
Publication Date
March 2015
Volume
169
Issue
3
Start / End Page
315 / 322
Location
United States
Related Subject Headings
- beta-Alanine
- Treatment Outcome
- Thiophenes
- Rivaroxaban
- Morpholines
- Humans
- Factor Xa Inhibitors
- Dabigatran
- Clinical Trials, Phase III as Topic
- Cardiovascular System & Hematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Krishnamoorthy, A., Sherwood, M. W., Lopes, R. D., & Becker, R. C. (2015). The periprocedural management of novel oral anticoagulants in patients with nonvalvular atrial fibrillation: rationale and a summary of the available evidence from phase 3 clinical trials. Am Heart J, 169(3), 315–322. https://doi.org/10.1016/j.ahj.2014.12.008
Krishnamoorthy, Arun, Matthew W. Sherwood, Renato D. Lopes, and Richard C. Becker. “The periprocedural management of novel oral anticoagulants in patients with nonvalvular atrial fibrillation: rationale and a summary of the available evidence from phase 3 clinical trials.” Am Heart J 169, no. 3 (March 2015): 315–22. https://doi.org/10.1016/j.ahj.2014.12.008.
Krishnamoorthy A, Sherwood MW, Lopes RD, Becker RC. The periprocedural management of novel oral anticoagulants in patients with nonvalvular atrial fibrillation: rationale and a summary of the available evidence from phase 3 clinical trials. Am Heart J. 2015 Mar;169(3):315–22.
Krishnamoorthy, Arun, et al. “The periprocedural management of novel oral anticoagulants in patients with nonvalvular atrial fibrillation: rationale and a summary of the available evidence from phase 3 clinical trials.” Am Heart J, vol. 169, no. 3, Mar. 2015, pp. 315–22. Pubmed, doi:10.1016/j.ahj.2014.12.008.
Krishnamoorthy A, Sherwood MW, Lopes RD, Becker RC. The periprocedural management of novel oral anticoagulants in patients with nonvalvular atrial fibrillation: rationale and a summary of the available evidence from phase 3 clinical trials. Am Heart J. 2015 Mar;169(3):315–322.
![Journal cover image](https://secure.syndetics.com/index.aspx?isbn=/lc.gif&issn=1097-6744&client=dukeuniv)
Published In
Am Heart J
DOI
EISSN
1097-6744
Publication Date
March 2015
Volume
169
Issue
3
Start / End Page
315 / 322
Location
United States
Related Subject Headings
- beta-Alanine
- Treatment Outcome
- Thiophenes
- Rivaroxaban
- Morpholines
- Humans
- Factor Xa Inhibitors
- Dabigatran
- Clinical Trials, Phase III as Topic
- Cardiovascular System & Hematology